Turkish Journal of Nephrology
Original Article

Evaluation of Kidney Function in Patients on Chemotherapy

1.

Azerbaijan Medical University, Educational-Therapeutic Clinic Nephrology and Efferent Therapy Center, Baku, Republic of Azerbaijan

2.

Department of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey

3.

Department of Medical Oncology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey

4.

Department of Biostatistics, Bezmialem Vakif University, School of Medicine, Istanbul, Turkey

Turkish J Nephrol 2021; 30: 138-144
DOI: 10.5152/turkjnephrol.2021.4434
Read: 354 Downloads: 181 Published: 16 June 2021

Objective: We aimed to study whether long-term kidney function would be affected by different chemotherapy regimens
in patients with malignancy.

Methods: In this study, 500 cancer patients between the ages of 18 and 85 years were included. Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was used to evaluate renal function. Patients with eGFR less than 60 mL/min/1.73 m2 before chemotherapy were excluded. Demographic and clinical data were recorded. Patients were divided into 4 groups according to the chemotherapy protocols: cisplatin-containing regimens, carboplatin-containing regimens, oxaliplatin-containing regimens, and platinum-free regimens. eGFR, urea, and creatinine values of 0th, 7th, 30th,and 180th days were recorded.

Results: In 180 days of treatment, eGFR decreased in 69 (13.8%) patients, whereas it increased in 46 (9.2%) patients (P = .001) and remained unchanged in 385 patients (77%). The cisplatin group had lower eGFR at the 180th day compared to the carboplatin (P = .033), oxaliplatin (P = .007), and platinum-free groups (P < .001). The median eGFR at the 180th day as lower in the cisplatin group compared to baseline (P < .001), while eGFR levels were not changed in the carboplatin and oxaliplatin groups and were significantly increased in the platinum-free group (P = .004).

Conclusion: Cisplatin-based treatment protocols were shown to worsen renal function during long-term follow-up. It is important to monitor kidney function closely for early intervention.

Cite this article as: Haziyev E, Gursu M, Seker M, et al. Evaluation of kidney function in patients on chemotherapy. Turk J Nephrol. 2021; 30(2): 138-144.

Files
EISSN 2667-4440